Our results show that SZYQD and its key compound luteolin can relieve asthma symptoms through the mechanisms predicted by network pharmacology, such as reducing overexpression of IL-6 and MUC5AC, inhibiting activation of the EGFR-AKT pathway and NF-κB pathway to inhibit inflammation and mucus overproduction. Here, NFKB1 is linked to asthma.